The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10361861" target="_blank" >RIV/00216208:11110/17:10361861 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/17:10361861

Result on the web

<a href="http://dx.doi.org/10.5603/KP.a2016.0135" target="_blank" >http://dx.doi.org/10.5603/KP.a2016.0135</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5603/KP.a2016.0135" target="_blank" >10.5603/KP.a2016.0135</a>

Result language

angličtina

Original language name

The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial

Original language description

Background and aim: The aim of the trial was to establish the efficacy and safety of Valsacor (R) (valsartan) and Valsacombi (R) (combination of valsartan and hydrochlorothiazide) in a wide variety of patient populations with mild to moderate arterial hypertension. Methods: We performed an international, multicentre, open-label, prospective trial. After one week of washout in previously treated patients, the patients were treated for 16 weeks according to the protocol. Naive patients entered the treatment period immediately. During the active treatment, four visits were planned for each patient to obtain the data for the primary and secondary efficacy endpoints analysis. The principal methods were blood pressure (BP) measurement, additionally in a subgroup of patients, assessment of erectile function. The initial dosage of valsartan 80 mg/day was titrated up to 320 mg/day to achieve the BP goal, with the addition of hydrochlorothiazide (HCTZ) in a fixed-dose combination (FDC), if needed. Results: Mean +/- standard deviation changes from baseline at week 16 were -26.6 +/- 10.4 mm Hg (systolic BP) and -14.8 +/- 7.6 mm Hg (diastolic BP). A total of 91% of the patients treated with either valsartan or valsartan FDC achieved the BP goal. Adverse reactions were experienced by 7.1% of the patients, with the most common being headache (1.9%), palpitation (1.6%), dizziness (1.6%), and fatigue (1.6%), during the whole trial. Conclusions: The results of the VICTORY trial show that valsartan and valsartan FDC effectively reduce the BP in patients with mild to moderate arterial hypertension and have a good tolerability profile.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Kardiologia Polska

ISSN

0022-9032

e-ISSN

—

Volume of the periodical

75

Issue of the periodical within the volume

1

Country of publishing house

PL - POLAND

Number of pages

10

Pages from-to

55-64

UT code for WoS article

000394705500009

EID of the result in the Scopus database

2-s2.0-85013293328